BBIO Stock Analysis: BridgeBio Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 15.617m USD | 12M Return: 69.7% | US10806X1028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 182M
Qual. Beats: -3
Rev. Trend: 81.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BridgeBio Pharma, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and delivering treatments for patients with genetic diseases. The company operates in the biotechnology sub-sector of healthcare, targeting rare and monogenic conditions with high unmet medical need. Its commercial portfolio includes Attruby, an oral TTR stabilizer for transthyretin amyloid cardiomyopathy, and NULIBRY (Fosdenopterin) for molybdenum cofactor deficiency.
The companys pipeline spans multiple late-stage clinical programs, including low-dose infigratinib (Phase 3) for achondroplasia, Encaleret (Phase 3) for hypoparathyroidism-related disorders, BBP-418 (Phase 3) for LGMD2I, and BBP-812, an AAV-based gene therapy for Canavan disease. BridgeBio also pursues programs in oncology and gene therapy, supported by licensing and collaboration agreements with partners such as Bayer, Alexion, Stanford University, and Novartis. Founded in 2015 and headquartered in Palo Alto, California, the company went public in 2019 and is listed on NASDAQ under the ticker BBIO.
- Attruby launch gains traction against Pfizers tafamidis ATTR-CM franchise
- Phase 3 readouts expected for infigratinib, encaleret, and BBP-418 pipeline
- Path to profitability depends on Attruby revenue scaling versus operating burn rate
| Net Income: -696.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 13.15 > 1.0 |
| NWC/Revenue: 29.27% < 20% (prev 312.3%; Δ -283.0% < -1%) |
| CFO/TA -0.48 > 3% & CFO -586.6m > Net Income -696.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.8m) vs 12m ago 2.77% < -2% |
| Gross Margin: 93.14% > 18% (prev 96.19%; Δ -3.05% > 0.5%) |
| Asset Turnover: 60.23% > 50% (prev 21.83%; Δ 38.39% > 0%) |
| Interest Coverage Ratio: -6.86 > 6 (EBIT TTM -616.3m / Interest Expense TTM 89.8m) |
| A: 0.17 (Total Current Assets 1.09b - Total Current Liabilities 890.6m) / Total Assets 1.22b |
| B: -3.40 (Retained Earnings -4.14b / Total Assets 1.22b) |
| C: -0.54 (EBIT TTM -616.3m / Avg Total Assets 1.15b) |
| D: -0.68 (Book Value of Equity -2.52b / Total Liabilities 3.72b) |
| Altman-Z'' = -14.30 = D |
| DSRI: 1.13 (Receivables 254.5m/76.9m, Revenue 691.8m/235.8m) |
| GMI: 1.03 (GM 96.19% / 93.14%) |
| AQI: 0.58 (AQ_t 0.08 / AQ_t-1 0.14) |
| SGI: 2.93 (Revenue 691.8m / 235.8m) |
| TATA: -0.09 (NI -696.2m - CFO -586.6m) / TA 1.22b) |
| Beneish M = -1.76 (Cap -4..+1) = CCC |
As of August 21, 2026, the stock is trading at USD 82.94 with a total of 2,030,457 shares traded. Over the past week, the price has changed by +2.13%, over one month by +2.70%, over three months by +21.58% and over the past year by +69.68%.
Current recommended Stop Loss: 76.90 (which is 7.3% or 2 ATR below the current price).
BridgeBio Pharma has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy BBIO.
- StrongBuy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 108.4 | 30.7% |
P/S = 22.7496
P/B = 123.6828
Revenue TTM = 691.8m USD
EBIT TTM = -616.3m USD
EBITDA TTM = -602.8m USD
Long Term Debt = 1.85b USD (from longTermDebt, last fiscal year)
Short Term Debt = 551.3m USD (from shortTermDebt, last quarter)
Debt = 2.51b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.7m
Net Debt = 1.79b USD (calculated: Debt 2.51b - CCE 720.2m)
Enterprise Value = 17.4b USD (15.6b + Debt 2.51b - CCE 720.2m)
Interest Coverage Ratio = -6.86 (Ebit TTM -616.3m / Interest Expense TTM 89.8m)
EV/FCF = -29.40x (Enterprise Value 17.4b / FCF TTM -592.1m)
FCF Yield = -3.40% (FCF TTM -592.1m / Enterprise Value 17.4b)
FCF Margin = -85.59% (FCF TTM -592.1m / Revenue TTM 691.8m)
Net Margin = -100.6% (Net Income TTM -696.2m / Revenue TTM 691.8m)
Gross Margin = 93.14% ((Revenue TTM 691.8m - Cost of Revenue TTM 47.5m) / Revenue TTM)
Gross Margin QoQ = 93.24% (prev 94.64%)
Tobins Q-Ratio = 14.30 (Enterprise Value 17.4b / Total Assets 1.22b)
Interest Expense / Debt = 3.58% (Interest Expense 89.8m / Debt 2.51b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -486.9m (EBIT -616.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 1.09b / Total Current Liabilities 890.6m)
Debt / Equity = -1.00 (negative equity) (Debt 2.51b / totalStockholderEquity, last quarter -2.52b)
Debt / EBITDA = -2.97 (negative EBITDA) (Net Debt 1.79b / EBITDA -602.8m)
Debt / FCF = -3.03 (negative FCF - burning cash) (Net Debt 1.79b / FCF TTM -592.1m)
Total Stockholder Equity = -2.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -60.61% (Net Income -696.2m / Total Assets 1.22b)
RoE = 31.67% (negative equity) (Net Income TTM -696.2m / Total Stockholder Equity -2.20b)
RoCE = 178.1% (negative capital employed) (EBIT -616.3m / Capital Employed (Equity -2.20b + L.T.Debt 1.85b))
RoIC = -57.74% (negative operating profit) (NOPAT -486.9m / Invested Capital 843.3m)
WACC = 8.06% (E(15.6b)/V(18.1b) * Re(8.90%) + D(2.51b)/V(18.1b) * Rd(3.58%) * (1-Tc(0.21)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.55 | Cagr: 4.14%
[DCF] Fair Price = unknown (Cash Flow -592.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.84 | # QB: -3
Revenue Correlation: 81.52 | Revenue CAGR: 263.8% | SUE: 0.08 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.60 | Chg30d=-29.09% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.68 | Chg30d=-24.81% | Revisions=-12% | GrowthEPS=+29.0% | GrowthRev=+102.1%
EPS next Year (2027-12-31): EPS=0.15 | Chg30d=-74.04% | Revisions=+38% | GrowthEPS=+105.7% | GrowthRev=+67.0%
[Analyst] Revisions Ratio: +13% (up=7, down=5)